



16th Vaccine Congress

12–14 September 2022 • Riva del Garda Congress Centre, Lake Garda, Italy



Programme Outline

Sunday 11 September 2022

17:00-18:30 Registration and Welcome Drinks Reception
Room: Palavela

Monday 12 September 2022

09:00-10:30 **OPENING PLENARY SESSION**
Chair: Gregory A. Poland, Paolo Bonnani
Room: Garda

09:00-09:10 Opening remarks
Conference Chair and Local Chair, Gregory A. Poland and Paolo Bonanni

09:10-09:50 **KN01 - Winner of the Schneerson-Robbins Prize**
The trillion dollar vaccine gap
Rino Rappuoli, *GlaxoSmithKline Vaccines, Italy*

09:50-10:30 **KN02 - Winner of Edward Jenner Vaccine Prize**
My life with Varicella-Zoster virus
Myron Levin, *University of Colorado, USA*

10:30-11:00 Refreshment break
Room: Palavela

11:00-11:30 **EARLY CAREER SCIENTIST AWARD**
Chair: Gregory A. Poland
Room: Garda

11:00-11:30 **KN03 - Winner of the Early Career Scientist Award**
Immune responses induced by SARS-CoV-2 vaccinations
Daniela Weiskopf, *La Jolla Institute for Immunology, USA*

11:30-13:00 **BREAKOUT SESSION 1**
T-cells and Viral Vaccines (COVID and Others)
Chair: Ivan Hung, Rick Kennedy
Room: Garda

BREAKOUT SESSION 2
Novel Vaccine Platforms
Chairs: Angie Rasmussen, Myron Levin
Room: Dolomiti

11:30-12:00 **INV01 - Immune responses against virus-infections and vaccinations: Identification of biomarkers of susceptibility to improve vaccination strategies in older adults**
Alper Cevirgel¹, Sudarshan Shetty^{2,1}, Martijn Vos¹, Nening Nanlohy¹, Lisa Beckers¹, Elske Bijvank¹, Nynke Rots¹, Josine van Beek¹, Anne Marie Buisman¹, **Debbie van Baarle**^{2,1}
¹National Institute for Public Health and the Environment, The Netherlands. ²University Medical Center, The Netherlands

INV02 - Trivalent HSV-2 mRNA-lipid nanoparticle vaccine for preventing genital herpes
Harvey Freidman, *University of Pennsylvania, USA*

12:00-12:15 **O1.1 - Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients.**
Dinesh Mohanraj¹, Alison Whitelegg², Satbeer Singh³, Alun Gordon³, Samuel Baldwin³
¹The University of Manchester Faculty of Biology Medicine and Health, UK. ²University Hospital Southampton NHS Foundation Trust, UK ³Portsmouth Hospitals University NHS Trust, UK

O2.1 - Multiple exposure to SARS-CoV-2 enhances cross-neutralizing antibodies to antigenically distinct, non-exposed variants
Annika Rössler¹, Antonia Netzl², Ludwig Knabl³, Helena Schäfer¹, Samuel H. Wilks², David Bante¹, Barbara Falkensammer¹, Wegene Borena¹, Dorothee von Laer¹, Derek Smith², **Janine Kimpel**¹
¹Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria. ²University of Cambridge, Center for Pathogen Evolution, Department of Zoology, Cambridge, UK. ³Tyrolpath Obrist Brunhuber GmbH, Zams, Austria

12:15-12:30 **O1.2 - SARS-CoV-2 infection in vaccinees induces virus-specific nasal-resident CD8 and CD4 T cells of broad specificity**
Joey Ming Er Lim¹, Anthony Tanoto Tan¹, Nina Le Bert¹, Shou Kit Hang¹, Adeline Chia¹, Jenny Guek Hong Low², Antonio Bertoletti¹

O2.2 - A Novel Intranasal Protein Subunit Vaccine for *Pseudomonas aeruginosa*
Adiya Katseff¹, Eman Barahim¹, Christina Toumanios¹, Alison McCormick², Paul Arnaboldi^{1,3,4}
¹New York Medical College, Valhalla, USA. ²Touro University, California, Vallejo, USA. ³Biopeptides, Corp.,

	¹ Duke-NUS Medical School, Singapore, Singapore. ² Singapore General Hospital, Singapore, Singapore	East Setauket, USA. ⁴ Lovelace Biomedical Research Institute, Albuquerque, USA
12:30-12:45	O1.3 - Generation of multiple SARS-CoV2-specific immune response in vivo by epitope-based nanoparticle vaccine in humanized ACE2 transgenic mouse model Iliyan Manoylov ¹ , Nikolina Mihaylova ¹ , Nikola Ralchev ¹ , Silviya Bradyanova ¹ , Irini Doytchinova ² , Andrey Tchorbanov¹ ¹ Institute of Microbiology, Bulgarian Academy of Sciences, Bulgaria. ² Faculty of Pharmacy, Medical University of Sofia, Bulgaria	O2.3 - Linear DNA amplicons as veterinary Covid-19 vaccine candidate Antonella Conforti¹ , Erika Salvatori ² , Lucia Lione ² , Mirco Compagnone ³ , Eleonora Pinto ² , Brian Viscount ⁴ , James Hayward ⁴ , Clay Shorrocks ⁴ , Diego Diel ⁵ , Fabio Palombo ³ , Joe Impellizzeri ⁶ , Luigi Aurisicchio ^{1,2} ¹ Evvivax, Rome, Italy. ² Takis, Rome, Italy. ³ Neomatrix, Rome, Italy. ⁴ Adnas, New York, USA. ⁵ Cornell University, New York, USA. ⁶ Guardian Veterinary Services, New York, USA
12:45-13:00	O1.4 - Kinetics of the B and T-cell immune responses following the third dose of SARS-CoV-2 mRNA vaccines in patients with rheumatoid arthritis: a multicenter study Alessandra Aiello ¹ , Andrea Picchianti-Diamanti ² , Chiara Farroni ¹ , Bruno Laganà ² , Chiara Agrati ³ , Anna Rosa Garbuglia ⁴ , Silvia Meschi ⁴ , Daniele Lapa ⁴ , Gilda Cuzzi ¹ , Linda Petrone ¹ , Valentina Vanini ^{1,5} , Andrea Salmi ¹ , Anna Maria Gerarda Altera ¹ , Vincenzo Puro ⁶ , Palma Scolieri ⁷ , Vincenzo Bruzzese ⁷ , Maurizio Benucci ⁸ , Fabrizio Cantini ⁹ , Emanuele Nicastrì ¹⁰ , Delia Goletti¹ (not registered/no show) ¹ Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy. ² "Sapienza" University, S. Andrea University Hospital, Italy ³ Laboratory of Cellular Immunology, IRCCS, Italy ⁴ Laboratory of Virology, IRCCS, Italy. ⁵ UOS Professioni Sanitarie Tecniche, IRCCS, Italy. ⁶ UOC Emerging Infections and Centro di Riferimento AIDS (CRAIDS), IRCCS, Italy. ⁷ U.O.C. Hospital S. Spirito-Nuovo Regina Margherita, Italy. ⁸ Rheumatology Unit, S. Giovanni di Dio Hospital, Italy. ⁹ Rheumatology Department, Hospital of Prato, Italy. ¹⁰ Clinical Division of Infectious Diseases, IRCCS, Italy	O2.4 - Poly-γ-glutamic acid/Alum adjuvanted pH1N1 vaccine-immunized aged mice exhibit a significant increase in vaccine efficacy with a decrease in age-associated CD8+ T cell proportion in splenocytes Jihyun Yang, Jaemoo Kim, HARYOUNG POO KRIBB, Daejeon, Republic of Korea
13:00-14:00	Lunch Room: Palavela	
14:00-15:30	BREAKOUT SESSION 3 Vaccines against Vector Borne Diseases and NTD's Chairs: Tony Fooks, Maria Elena Bottazzi Room: Garda	BREAKOUT SESSION 4 Vaccine Hesitancy – education, communication, perceptions, protection and disease, emotional response Chair: Greg Poland, Jen Nelson Room: Dolomiti
14:00-14:30	INV03 - Naturally acquired and vaccine induced immunity to Ebola virus Miles Carroll, Oxford University, UK	INV04 - Addressing Vaccine Hesitancy: Integrating the Vaccine Trust Gauge and effective communication to advance confidence and uptake Scott Ratzan, CUNY School of Public Health and Health Policy, New York, USA

14:30-14:45	<p>O3.1 - Optimisation of dengue virus maturation and implications on vaccine efficacy in mice Connor Scott¹, Alberto Amarilla¹, Summa Bibby¹, Natalee Newton¹, Roy Hall^{1,2}, Jody Hobson-Peters^{1,2}, David Muller¹, Keith Chappell^{1,2}, Paul Young^{1,2}, Naphak Modhiran¹, Daniel Watterson^{1,2} ¹<i>School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia.</i> ²<i>Australian Infectious Disease Research Centre, The University of Queensland, St Lucia, Australia</i></p>	<p>O4.1 - Identifying factors that characterize resilient immunization programs: a systematic scoping review. Aomesh Bhatt¹, Luke Baxter¹, Lindsay Hermany², Alexandra Bhatti², Amanda Eiden², Rachel Mitrovich², Mark Connolly³, Mawuli Nyaku², Rebecca Slater¹ ¹<i>University of Oxford, Oxford, UK.</i> ²<i>Merck & Co, Inc, Kenilworth, USA.</i> ³<i>GMAS, Charlotte, USA</i></p>
14:45-15:00	<p>O3.2 - Evaluating the efficacy and correlates of protection for an insect-specific flavivirus vectored Zika vaccine. Albert Auguste, Danielle Porier, Manette Tanelus <i>Virginia Tech, USA</i></p>	<p>O4.2 - Community-specific personal stories improve HPV vaccine attitudes in a Christian population in the United States David Redd, Jamie Jensen, Chantel Sloan-Aagard, Brian Poole, <i>Brigham Young University, Provo, USA</i></p>
15:00-15:15	<p>O3.3 - Baseline human immune determinants of yellow fever live-attenuated vaccine immunogenicity Justin Ooi¹, Clara Koh¹, Eugenia Ong², Candice Chan³, Esther Gan¹, Noor Zayanah Hamis¹, Laura Rivino⁴, Jenny Low³, Eng Eong Ooi^{1,2,5}, Kuan Rong Chan¹ ¹<i>Duke-NUS Medical School, Singapore.</i> ²<i>Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</i> ³<i>Department of Infectious Diseases, Singapore General Hospital, Singapore.</i> ⁴<i>School of Cellular and Molecular Medicine, University of Bristol, UK.</i> ⁵<i>Saw Swee Hock School of Public Health, National University of Singapore, Singapore</i></p>	<p>O4.3 - Vaccine wars in the 21st century: A clash of world views Gregory A Poland, <i>Mayo Clinic, USA</i></p>
15:15-15:30	<p>O3.4 - A single nucleotide U59C substitution in the dengue virus 5' untranslated region destabilized an attenuating mutation in mosquitoes. Amanda Bifani¹, Hwee Cheng Tan¹, Dorothy Ng², Kitti Chan¹, Subhash Vasudevan¹, Milly Choy¹, Eng Eong Ooi¹ ¹<i>Duke-NUS Medical School, Singapore,</i> ²<i>SingHealth, Singapore</i></p>	
15:30-16:00	Refreshment break <i>Room: Palavela</i>	
16:00-17:30	<p>BREAKOUT SESSION 5 New Regulatory Pathways for Urgent Vaccines <i>Chairs: Ken Ishii, Carlos del Rio</i> <i>Room: Garda</i></p>	<p>BREAKOUT SESSION 6 Vaccine Platforms, Vectors and Delivery Systems (patches, time release) <i>Chairs: Ivan Hung, Danny Altmann</i> <i>Room: Dolomiti</i></p>
16:00-16:30	<p>INV05 - Immunobridging strategies for urgent vaccines: reality or fantasy? Phil Krause <i>Independent Consultant, USA</i></p>	<p>*INV06 - Improving (COVID) vaccines by intradermal self-administration Yotam Levin, Dean Kamen, Efrat Kochba <i>NanoPass, Israel</i> <i>One presentation will be given remotely</i></p>
16:30-16:45	<p>O5.1 - How to accelerate the supply of vaccines to all populations worldwide - A regulatory perspective Mic McGoldrick¹, Thierry Gastineau² ¹<i>International Federation of Pharmaceutical Manufacturers and Associations, Switzerland.</i> ²<i>Vaccines Europe, Belgium</i></p>	<p>O6.1 - Development of Heat Stable Oral Vaccines for Coronavirus John Howard <i>Applied Biotechnology Institute Inc., USA</i></p>
16:45-17:00	<p>O5.2 Development of a revised 'Barriers to Care' conceptual framework and its application to vaccination policy and practice during the COVID-19 pandemic Anna Larson, Rachel Mitrovich, <i>Merck & Co., Inc., USA</i></p>	<p>O6.2 Availability of the highly attenuated replication-competent vaccinia virus strain LC16m8Δ as a COVID-19 vaccine platform Akihiko Sakamoto¹, Hiroaki Osawa¹, Tetsushi Mizuno¹, Hinata Hashimoto¹, Kyouhei Yamagata¹, Saya Yamauchi¹, Keigo Mitsuhashi¹, Ryohei Ogawa², Mitsuhiro Iyori¹, Hisatoshi Shida³, Shigeto Yoshida¹ ¹<i>Kanazawa University, Ishikawa, Japan.</i> ²<i>Toyama University, Japan.</i> ³<i>Hokkaido University, Japan</i></p>

17:00-17:15	O5.3 - Critical success factors for conducting human challenge trials for vaccine development in low- and middle-income countries. Keiko Msusa ¹ , Taryn Rogalski-Salter ² , Henshaw Mandi ³ , Ralf Clemens ¹ ¹ University of Siena, Institute for Global Health, Italy ² Bill and Melinda Gates Medical Research Institute, USA. ³ Coalition for Epidemic Preparedness Innovations, Norway	O6.3 - GMMA for the development of an O-antigen based vaccine against Shigella Francesca Mancini, Roberta Di Benedetto, Valentina Caradonna, Maria Grazia Aruta, Carlo Giannelli, Mariagrazia Pizza, Omar Rossi , Francesca Micoli GSK Vaccines Institute for Global health, Italy
17:15-17:30	O5.4 - ACE2 inhibition assay as an effective surrogate for SARS-CoV-2 neutralisation Tom Tipton ¹ , Stephanie Longet ¹ , Stephen Laidlaw ¹ , Dung Nguyen ¹ , Susanna Dunachie ¹ , Paul Klanerman ¹ , William James ¹ , Ellie Barnes ¹ , Thushan de Silva ² , Miles Carroll ¹ ¹ University of Oxford, UK. ² University of Sheffield, UK	O6.4 - Env-2dCD4S60C complexes elicit potent, broadly neutralizing antibodies against clinically relevant viruses in Chinese-origin rhesus macaques. Roberto Carlos Rebelo Pereira, Mark Andrew Killick , Maria Antonia Papatheanasopoulos HIV Pathogenesis Research Unit, University of the Witwatersrand, South Africa
17:30-19:00	Drinks Reception, Poster Session 1 Room: Palavela No shows: P1.06, P1.14, P1.21	
18:30-19:30	Meet the Editors Session Chair: Greg Poland Room: Garda	Scott Ratzan Roundtable: Statement on Multisectoral Actions for Building Trust to Promote Vaccine Acceptance Chair: Scott Ratzan, Lauren Rauh Room: Dolomiti
Tuesday 13 September 2022		
08:00-09:00	Researcher Academy – Early/Mid Career Fundamentals of Peer Review Chair: Dior Beerens Room: Garda	Infectious Diseases Clinical Research Consortium (IDCRC) Symposium: New Studies from the Vaccine and Treatment Evaluation Units (VTEUs) Chair: Paul Spearman Room: Dolomiti
09:00-11:00	PLENARY SESSION 2 COVID and COVID Vaccines Chair: Greg Poland, Carlos del Rio Room: Garda	
09:00-09:30	KN04 - Academic Creativity, Strategic Alliances and Diplomacy: Behind the scenes for the development of CORBEVAX, a protein subunit COVID-19 vaccine Maria Elena Bottazzi , Baylor College of Medicine, USA	
09:30-10:00	KN05 - Antibody as a Correlate of Protection to SARS-CoV-2 following natural infection and vaccination David Goldblatt , University College London, UK <i>Presentation will be given remotely</i>	
10:00-10:30	KN06 - SARS-CoV-2 human infection challenge to accelerate vaccine development Christopher Chiu , Imperial College London, UK	
10:30-11:00	Panel Discussion <i>All speakers, COVID and next steps</i>	
11:00-11:30	Refreshment break Room: Palavela	
11:30-13:00	BREAKOUT SESSION 7 New Pneumococcal and Meningococcal Vaccines Chairs: Ivan Hung, Carlos del Rio Room: Garda	BREAKOUT 8 Celebrating successes (but you can't stop there) Polio, measles, positive impacts and the role of Clinical Trial networks Chair: Helena Maltezo, Rick Kennedy Room: Dolomiti
11:30-12:00	INV07 - Development of low-cost pneumococcal and meningococcal vaccines for low and middle-income countries: lessons learned Mark Alderson PATH, USA	INV08 - Eradicating Poliovirus: how much is still missing? Silvio Tafuri , Francesco Paolo Bianchi Aldo Moro University of Bari, Italy
12:00-12:15	O7.1 - A nanotechnological approach to potentiate the immunogenicity of pneumococcal glycoconjugate vaccines Maruthi Prasanna ^{1,2} , Rubén Varela Calvino ² , Daphnée Soulard ³ , Lorenzo Albertazzi ⁴ , Annie Lambert ¹ , Sylvia Pujals ⁴ , François Trottein ³ , Emilie Camberlein ¹ , Noemi Csaba ² , Cyrille Grandjean ¹	O8.1 - Morbidity and absenteeism among healthcare personnel in the context of a mandatory COVID-19 vaccination policy Helena Maltezo , National Public Health Organization in Athens, Greece

	¹ Nantes University UMR CNRS 6286, France ² CIMUS University of Santiago de Compostela, Spain. ³ CILL Inserm U1019, CNRS UMR 8204 Pasteur Institute of Lille, France. ⁴ Nanoscopy for Nanomedicine, Institute for Bioengineering of Catalonia, Spain	
12:15-12:30	07.2 Is the more the better? Assessing whether sugar-coating pneumococcal bioconjugates boosts their immunogenicity Marta Mauri ¹ , Emily Kay ¹ , Giuseppe Ercoli ² , Jeremy Brown ² , Brendan Wren ¹ ¹ LSHTM, UK. ² UCL, UK	
12:30-12:45	07.3 Using LASSO regression to estimate the population-level impact of pneumococcal conjugate vaccines Anabelle Wong ^{1,2} , Sarah Kramer ¹ , Marco Piccininni ^{3,4} , Jessica Rohmann ^{3,4} , Tobias Kurth ² , Sylvie Escolano ⁵ , Matthieu Domenech de Cellès ¹ ¹ Max Planck Institute for Infection Biology, Germany. ² Charité – Universitätsmedizin Berlin, Germany. ³ Institute of Public Health, Charité – Universitätsmedizin, Berlin, Germany. ⁴ Center for Stroke Research Berlin, Germany. ⁵ Université Paris-Saclay, UVSQ, Université Paris-Sud CESP, France	08.2 - A cross-sectional analysis of COVID-19 vaccine clinical trials in Africa Lindi Mathebula ¹ , Charles S. Wiysonge ^{1,2,3} , Duduzile Ndwandwe ¹ ¹ Cochrane South Africa, South African Medical Research Council, South Africa. ² Centre for Evidence-based Health Care, Stellenbosch University, South Africa. ³ Division of Epidemiology and Biostatistics, University of Cape Town., South Africa
12:45-13:00	07.4 - Effectiveness and safety of meningococcal quadrivalent conjugate vaccines: a systematic review Massimiliano Panella, Chiara Sacchi, Gaia Broglia, Fabrizia Risi, Fancesco Barone Adesi, Andrea Conti <i>Università degli Studi del Piemonte Orientale, Novara, Italy</i>	08.4 - Strategic introduction of the RTS,S/AS01 malaria vaccine relative to scale-up of existing interventions Hillary M. Topazian, Nora Schmit, Ines Gerard-Ursin, Giovanni D. Charles, Azra C. Ghani, Peter Winskill <i>Imperial College London, UK</i>
13:00-14:00	Lunch Break <i>Room: Palavela</i>	
	BREAKOUT SESSION 9 Influenza, new adjuvants including Laser <i>Chairs: Florian Krammer, Ken Ishii</i> <i>Room: Garda</i>	BREAKOUT SESSION 10 mRNA Vaccines – the future and sustainability <i>Chairs Angie Rasmussen, Amy Chung</i> <i>Room: Dolomiti</i>
14:00-14.30	INV09 - Maturation of B cell Responses to mRNA Vaccines in Humans Ali Ellebedy , Washington University School of Medicine, USA <i>Presentation will be given remotely</i>	INV10 - mRNA Variant Boosting on Immunity and Protection in NHP: How we Move Forward With Vaccine Design and Delivery Robert Seder , Vaccine Research Center, NIAID, USA
14.30-14.45	09.1 - Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine Jake S. O'Donnell ^{1,2} , Ariel Isaacs ^{1,2} , Virginie Jakob ³ , Celia Lebas ³ , James Barnes ⁴ , Patrick C. Reading ⁴ , Paul R. Young ⁵ , Daniel Watterson ⁵ , Patrice M. Dubois ³ , Nicolas Collin ³ , Keith J. Chappell ^{1,5,6} ¹ The Australian Institute for Bioengineering and Nanotechnology, Australia. ² The School of Chemistry and Molecular Biosciences, The University of Queensland, Australia. ³ Vaccine Formulation Institute, Switzerland. ⁴ The WHO Collaborating Centre for Reference and Research on Influenza, at The Peter Doherty Institute for Infection and Immunity, Australia. ⁵ The School of Chemistry and Molecular Biosciences, The University of Queensland, Australia. ⁶ Australian Infectious Disease Research Centre, The University of Queensland, Australia	010.1 - A trans-amplifying RNA vaccine candidate induces a specific immune response that protects mice against chikungunya virus infections. Christin Schmidt ¹ , Erik Haefner ¹ , Julia Gerbeth ¹ , Tim Beissert ² , Ugur Sahin ² , Mario Perkovic ² , Barbara S. Schnierle ¹ ¹ Department of Virology, Paul-Ehrlich-Institut, Germany. ² TRON (Translational Oncology at the University Medical Center), Johannes Gutenberg University Mainz, Germany
14:45-15:00	09.2 - Development and implementation of the global Influenza Vaccines R&D Roadmap Kristine Moore ¹ , Julie Ostrowsky ¹ , Anje Mehr ¹ , Angela Ulrich ¹ , Michael Osterholm ¹ , Joseph Bresee ² , Christopher Chadwick ³ , Martin Friede ³ , Bruce Gellin ⁴ , Josie Golding ⁵ , Peter Hart ⁵ , Stacey Knobler ⁶ , Ann Moen ⁷ ¹ University of Minnesota, USA. ² Taskforce for Global Health, USA. ³ World Health Organization,	010.2 - Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection Salma Sheikh-Mohamed ¹ , Gary Chao ¹ , Baweleta Isho ¹ , Gili Regev ² , Sharon Straus ³ , Anne-Claude Gingras ⁴ , Jen Gommerman ¹ ¹ University of Toronto, Canada. ² Sheba

	Switzerland. ⁴ The Rockefeller Foundation, USA. ⁵ Wellcome Trust, UK. ⁶ Sabin Vaccine Institute, USA. ⁷ Centers for Disease Control and Prevention, USA	Medical Centre, Israel. ³ St. Michael's Hospital, Canada. ⁴ Mount Sinai, Canada
15:00-15:15	O9.3 - Transcriptomic signatures of humoral response to high dose and adjuvanted influenza vaccine in the elderly population Inna Ovsyannikova ¹ , Richard Kennedy ² , Gregory Poland ² ¹ Mayo Clinic Vaccine Research Group, USA. ² Mayo Clinic Vaccine Research Group, USA	O10.3 - Safety and Immunogenicity of mRNA-1345, an mRNA-Based Vaccine Against Respiratory Syncytial Virus in Older Adults Grace Chen ¹ , Runa Mithani ¹ , Archana Kapoor ¹ , Sophia Lu ¹ , Christine A. Shaw ¹ , Sonia K. Stoszek ¹ , Allison August ² ¹ Moderna, Inc., USA. ² Moderna, Inc, USA
15:15-15:30	O9.4 -Innovative multi-component adjuvants induce sustained multi-functional anti-Influenza A responses in guinea pigs Emmelie Eckhardt ¹ , Ger Van Zandbergen ² , Max Bastian ¹ ¹ Friedrich-Loeffler-Institut, Germany. ² Paul-Ehrlich-Institut, Germany	O10.4 - COVID-19 mRNA vaccination drives differential mucosal neutralising antibody profiles in naïve and SARS-CoV-2 previously infected individuals Stephanie Longet ¹ , Alexander Hargreaves ¹ , Saoirse Healy ¹ , Rebecca Brown ² , Hailey R Hornsby ² , Naomi Meardon ³ , Tom Tipton ¹ , Eleanor Barnes ^{1,4} , Susanna Dunachie ^{1,4,5} , Christopher JA Duncan ^{6,7} , Paul Klenerman ^{1,4} , Alex Richter ^{8,9} , Lance Turtle ^{10,11} , Thushan I de Silva ^{2,3} , Miles W Carroll ¹ ¹ University of Oxford, UK ² University of Sheffield, UK ³ Sheffield Teaching Hospitals NHS Foundation Trust, UK ⁴ Oxford University Hospitals NHS Foundation Trust, UK ⁵ Mahidol-Oxford Tropical Medicine Research Unit, Thailand ⁶ Newcastle University, UK ⁷ Newcastle upon Tyne Hospitals NHS Foundation Trust, UK ⁸ University of Birmingham, UK. ⁹ University Hospitals Birmingham NHS Foundation Trust, UK. ¹⁰ University of Liverpool, UK ¹¹ Liverpool University Hospitals NHS Foundation Trust, UK
15:30-17:00	Refreshment break and Poster Session 2 Room: Palavela No shows: P2.01, P2.05, P2.06, P2.12, P2.31, P2.36, P2.38, P2.60, P2.61)	
17:00-18:30	BREAKOUT SESSION 11 - Panel discussion on Public Health Response in an Age of Politics and Science Scepticism Chairs: Gregory A. Poland and Paolo Bonanni Room: Garda Reflections on Pandemic Planning and Response: Pareto Efficiency or Nash Equilibrium? Gregory A. Poland Poland Science Communication and Combatting Disinformation About Public Health Angie Rasmussen Crisis communication in the age of social media Carlos del Rio Vaccination policies, issues of accessibility and beyond Helena Maltezou Discussion and Q&A	
19:30-22:00	Conference Dinner (ticket required)	
Wednesday 14 September 2022		
08:30-09:30	Hot Topic – Overview and Update on Monkeypox Greg Poland and Rick Kennedy Room: Garda Monkeypox immunology and vaccines Rick Kennedy An overview of monkeypox epidemiology, clinical presentation, and pandemic control Gregory A. Poland Discussion and Q&A	

09:30-11:30	PLENARY SESSION 3 Vaccine Safety Chairs: Jen Nelson, Danny Altmann Room: Garda	
09.30-10.00	KN07 - COVID-19 vaccination, fertility and pregnancy. How could we have done better? Victoria Male, <i>Imperial College London, UK</i>	
10:00-10:30	KN08 - Rapid Generation of Vaccine Safety Evidence During COVID-19 Nicola Klein, <i>Kaiser Permanente Vaccine Study Center, USA</i>	
10:30-11:00	KN09 - Vaccine safety surveillance in low- and middle-income countries Gagandeep Kang, <i>Christian Medical College, India</i>	
11:00-11:30	Refreshment break Room: Palavela	
11:30-13:00	BREAKOUT SESSION 12 Hot Topics Chair: Florian Krammer, Rick Kennedy Room: Garda	BREAKOUT SESSION 13 Veterinary and Agriculturally Important Vaccines Chairs: Tony Fooks, Amy Chung Room: Dolomiti
11:30-12:00	INV 11 - Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern Ashley St. John, <i>Duke – NUS Medical School, Singapore</i>	INV12 - African swine fever virus antigen discovery Chris Netherton, <i>Pirbright Institute, UK</i> <i>Presentation will be given remotely</i>
12:00-12:15	O11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphorylcholine as antigen Johan Frostegård ¹ Couldn't attend , Pritam Kumar Panda ² , Shailesh Samal ^{1,1} <i>Karolinska Institutet, Sweden</i> ² <i>Uppsala University, Sweden</i>	O12.1 - Epitope mapping of Schmallenberg Virus Nucleoprotein unveiled an immunogen that induces cell-mediated T CD8+ protection in IFNAR -/- mice. Gabriel Guerra ¹ , Diego Barriales ² , Gema Lorenzo ³ , Sandra Moreno ³ , Juan Anguita ² , Alejandro Brun ³ , Nicola Abrescia ^{1,4,5,1} <i>Structure and Cell Biology of Viruses Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Spain.</i> ² <i>Inflammation and Macrophage Plasticity Laboratory, CIC bioGUNE-BRTA, Spain.</i> ³ <i>Animal Health Research Center (INIA-CISA), Spain.</i> ⁴ <i>Ikerbasque, Basque Foundation for Science, Spain.</i> ⁵ <i>CIBERehd, Instituto de Salud Carlos III, Spain</i>
12:15-12:30	O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2 Zoltan Banki ¹ , Jose Mateus ² , Annika Rössler ¹ , Helena Schäfer ¹ , David Bante ¹ , Lydia Riepler ¹ , Alba Grifoni ² , Alessandro Sette ^{2,3} , Viviana Simons ^{4,5,6,7} , Barbara Falkensammer ¹ , Hanno Ulmer ⁸ , Bianca Neurauter ¹ , Wegene Borena ¹ , Florian Krammer ^{4,5} , Dorothee von Laer ¹ , Daniela Weiskopf ² , Janine Kimpel¹ ¹ <i>Medical University of Innsbruck, Austria.</i> ² <i>Center for Infectious Disease and Vaccine Research, LJI USA.</i> ³ <i>University of California, San Diego (UCSD), USA.</i> ⁴ <i>Icahn School of Medicine at Mount Sinai, USA.</i> ⁵ <i>Department of Pathology, Icahn School of Medicine at Mount Sinai, USA.</i> ⁶ <i>Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, USA.</i> ⁷ <i>The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA.</i> ⁸ <i>Department of Medical Statistics, Medical University of Innsbruck, Austria</i>	O12.2 - The effect of vaccination against Campylobacter on gut immune responses and microbiota composition in chickens Noémie Gloanec ^{1,2,3} , Daniel Dory ¹ , Ségolène Quesne ² , Véronique Béven ¹ , Alassane Keita ⁴ , Marianne Chemaly ² , Muriel Guyard ² ¹ <i>GVB, French Agency for Food, Environmental and Occupational Health and Safety (ANSES), France.</i> ² <i>HQPAP (ANSES), France.</i> ³ <i>UFR of Life Sciences Environment, University of Rennes 1, France</i> ⁴ <i>SELEAC - Avian breeding and experimental Department, (ANSES), France</i>
12:30-12:45	O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng <i>Central Bank of Malaysia, Malaysia</i>	O12.3 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated <i>Piscirickettsia salmonis</i> vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva <i>Traingular Biotech, Chile</i>
12:45-13:00	O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan	O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 <i>Leptospira</i> spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina Jimenez, Rocío Herrera, Ligia Torres

	<i>City University of New York Graduate School of Public Health and Health Policy, USA</i>	<i>AGROSAVIA, Mosquera, Colombia</i>
13:00-13:15	Closing Session <i>Chairs: Greg Poland, Paolo Bonanni</i> <i>Room: Garda</i>	
13:30-13:40	Spotlight on Africa Chair: Helena Maltezou <i>Room: Dolomiti</i>	
13:40-14:00	SA1 - Vaccines, variants and immunity - a view from the South Wendy Burgers, University of Cape Town, South Africa	
14:00-14:20	SA2 - Vaccine Manufacturing: Spotlight on Africa Wilmot James¹ , Luc Debruyne ² , Azure Makadzange ³ , Stavros Nicolaou ⁴ , Lewis Rubin-Thompson ⁵ , Martin Veller ⁶ , Amadou Sall ⁷ ¹ <i>Columbia University, USA</i> ² <i>KU Leuven, Belgium</i> . ³ <i>Stanford University, USA</i> . ⁴ <i>Aspen Pharmacare, South Africa</i> . ⁵ <i>University of Rochester, USA</i> . ⁶ <i>University of the Witwatersrand, South Africa</i> ⁷ <i>Institute Pasteur, Senegal</i>	
14.20-14:40	SA3 - Capacity building and preparedness for high consequence emerging virus outbreak in west Africa Miles Carroll, Oxford University, UK	
14:40-15:00	SA4 - Effect of the COVID-19 pandemic on routine immunization in Africa Aisha Abubakar, International Society for Infectious Disease, USA, Ahmadu Bello University, Nigeria <i>Presentation will be given remotely</i>	
15:00-15:20	SA5 - HPV VACCINE HESITANCY IN PARENTS OF GIRLS AGED 9-14 YEARS IN RURAL COMMUNITIES OF NORTH WEST CAMEROON PRE-RECORDED PRESENTATION Lorraine Elit ^{1,2} , Glen Afugchwi ¹ , Calvin Ngalla³ , Eric Tum ⁴ , Joel Fokom-Domgue ⁵ , Elysee Nouvet ⁶ ¹ <i>Baptist Institute of Health Sciences, Cameroon</i> . ² <i>McMaster University, Canada</i> . ³ <i>Mbingo Hospital, Cameroon</i> . ⁴ <i>Information and Orientation Vocation Centre, Cameroon</i> . ⁵ <i>University of Yaounde, Cameroon</i> . ⁶ <i>Western University, Canada</i>	
15:20-15:40	Panel Discussion and Q&A	
15.40	Closing Networking and Refreshments Foyer	